Close Menu

NEW YORK – Thermo Fisher Scientific said on Wednesday that it is collaborating with WuXi Diagnostics and the Mayo Clinic to develop a COVID-19 total antibody test.

As part of the ongoing collaboration, Mayo Clinic is clinically evaluating the new assay, called Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test. Thermo Fisher will seek Emergency Use Authorization from the US Food and Drug Administration and international regulatory authorizations for the test over the next few weeks.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.